A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Einstein, David Johnson, Choudhury, Atish Dipankar, Saylor, Philip James, Patterson, Jesse Christopher, Croucher, Peter, Ridinger, Maya, Erlander, Mark G., Yaffe, Michael B., Bubley, Glenn
Published in Journal of clinical oncology (20.02.2022)
Published in Journal of clinical oncology (20.02.2022)
Get full text
Journal Article
A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Einstein, David Johnson, Choudhury, Atish Dipankar, Saylor, Philip James, Patterson, Jesse Christopher, Croucher, Peter, Ridinger, Maya, Erlander, Mark G., Yaffe, Michael B., Bubley, Glenn
Published in Journal of clinical oncology (20.02.2021)
Published in Journal of clinical oncology (20.02.2021)
Get full text
Journal Article
Combination of selective polo-like kinase 1 (PLK1) inhibitor PCM-075 with abiraterone in prostate cancer and non-androgen-driven cancer models
Patterson, Jesse Christopher, Varmeh, Shohreh, Erlander, Mark G., Yaffe, Michael B.
Published in Journal of clinical oncology (20.02.2018)
Published in Journal of clinical oncology (20.02.2018)
Get full text
Journal Article